Was Sevilleja v Marex Financial Ltd [2020] UKSC 31 regarding Reflective Loss Effectively Decided?
LSE Law Review · 09.04.2026 · 11 (2)
DOI: 10.61315/lselr.971 ↗Kurz gefasst
Fachartikel in der Zeitschrift LSE Law Review, online erschienen am 09.04.2026. Verfasst von Gulsum Qane. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
This research article focuses on a rather technical area of company law, known as reflective loss. The article builds on legal academia regarding the reflective loss principle, focusing on the courts’ approaches in leading decisions. Reflective loss refers to the resulting loss that is suffered by shareholders when a company suffers the consequences of a wrong. The article specifically focuses on the case of Sevilleja v Marex Financial Ltd [2020] UKSC 31, exploring whether the case was effectively or ineffectively decided through the lens of commentators, by analysing the majority and minority conclusions of the deciding judges in the UK Supreme Court. To resolve the unaddressed issues of the Supreme Court and to reduce their negative impact on individuals that bring forward claims for reflective loss, this article explores Alan Koh’s reform of the reflective loss principle. After all, the purpose of the law is to ensure justice, and legal reform can allow for fairness and equality for such corporations and its members, through enhancing areas that require improvement.
Zitieren
APA
Qane, G. (2026). Was Sevilleja v Marex Financial Ltd [2020] UKSC 31 regarding Reflective Loss Effectively Decided?. LSE Law Review, 11(2). https://doi.org/10.61315/lselr.971
Vancouver
Qane G. Was Sevilleja v Marex Financial Ltd [2020] UKSC 31 regarding Reflective Loss Effectively Decided?. LSE Law Review. 2026;11(2). doi:10.61315/lselr.971
BibTeX
@article{Qane2026,
author = {Qane, Gulsum},
title = {Was Sevilleja v Marex Financial Ltd [2020] UKSC 31 regarding Reflective Loss Effectively Decided?},
journal = {LSE Law Review},
year = {2026},
volume = {11},
number = {2},
doi = {10.61315/lselr.971}
}
EUVIMED